Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Ambit, Cephalon sign screening agreement
December 2006
by Randall C. Willis  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SAN DIEGO—Pharmaceutical companies Ambit Biosciences and Cephalon recently an-nounced the signing of a screen­ing, discovery and development agreement that will see the companies tackle kinases, key molecules in many disease path­ways. Working on two undis­closed kinase targets, Ambit will discover and deliver lead compounds, which Cephalon will pursue for preclinical and clinical development as well as commercialization.
 
For their services, Ambit will receive $18 million upfront and potential milestone payments up to $232.5 million, as well as roy­alties on the sales of any products arising from the collaboration.
 
"Kinase inhibition as a mecha­nism for novel therapeutics is complex, extremely challenging from the aspect of finding a drug­gable chemotype and information-intensive," says Dr. Jeffrey Vaught, Cephalon executive VP of R&D. "We recognized very early that a strategic alliance with a kinome-centric organization would com­pliment and strengthen our inter­nal capabilities.
 
"After evaluating several tech­nologies, we felt that Ambit had several important attributes that included: world-class technology, a scientific and management team that understood and were com­mitted to drug discovery and an impressive track record of accom­plishment."
 
According to Dr. Shripad Bhagwat, Ambit senior VP of drug discovery, Ambit will also screen Cephalon's kinase-focused library using KinomeScan to select novel leads for multiple undisclosed kinase targets of interest to Ambit. The company retains rights to pur­sue these leads independently to discover kinase inhibitor drugs.
 
Ambit's screening platform, KinomeScan, works by directly and quantitatively measuring competitive binding of small mol­ecules to the ATP binding site of kinases. What sets the system apart, says Dr. Patrick Zarrinkar, Ambit senior director of technolo­gy development and alliance man­agement, is the ability to screen compounds on a massively paral­lel scale and under identical condi­tions. For example, 10,000 com­pounds can be screened against a panel of approximately 300 kinas­es, yielding 3,000,000 data points in months rather than years.
 
"We are entering an era in kinase research which is very sim­ilar to that with GPCRs where the breadth of potential interaction of the compound can dictate, not only efficacy, but potential unwanted off-target activities and toxicity," Vaught says. "KinomeScan offers real-time data back to the synthe­sizing chemist to inform his/her next synthesis."
 
One of the challenges in devel­oping kinase inhibitors is the ubiq­uity of the proteins throughout the human proteome—some estimates suggest as many as 500 different kinases—and their pivotal role as a primary point-of-entry for many biological pathways. At present, KinomeScan includes 300 kinases.
 
"The representation of kinase subfamilies in Ambit's panel is comparable to their representation in the human kinome as a whole," Zarrinkar says. "Ambit's panel will continue to grow, and we antici­pate that within two to three years the panel will contain the vast majority, if not all, human protein kinases."
 
From Vaught's perspective, how­ever, the distribution of kinases may actually be a blessing rather than a curse.
 
"While there is a lot of discus­sion around kinase inhibitor selec­tivity, I am much more interested in the potential ability to specifi­cally target multiple mechanisms, built into a single compound, which pharmacologically can be demonstrated to be complimen­tary, important to the pathology of disease and synergistic when combined," he says. "This would be and is impossible without a full panel of data from which to instruct and guide the synthesiz­ing chemist."
 
Cephalon, it would seem, is bet­ting on KinomeScan as a way to access this information.
 
Code: E120603

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.